|
18F-FDG Clinical Trials
14 actively recruiting trials across 4 locations
Also known as: 18F-FDG injection, CT scan, Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg., PET scan, blood collection
Pipeline
Early 1: 5Phase 2: 2Phase 4: 2
Top Sponsors
- Hua Zhu3
- Peking University Cancer Hospital & Institute2
- Peking Union Medical College Hospital2
- University of California, Davis1
- University Medical Center Groningen1
Indications
- Cancer12
- Solid Tumor4
- Lung Cancer3
- Liver Disease2
- Type 1 Diabetes1
Other10 trials
Sacramento, California1 trial
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
UC Davis EXPLORER Molecular Imaging Center
Early 1
Bethesda, Maryland1 trial
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center
Phase 2
Englewood, New Jersey1 trial
Ultralow Dose PET Imaging of 18F-FDG Uptake
Nuclear Imaging Institute
Phase 2
New York, New York1 trial
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
New York VA Hospital
Phase 4
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.